Jury awards Biohaven and Yale $4M in trade secret case
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Alaska LNG shipping savings justifies billions in investment, developer says
- Citi cuts investment banking analyst program to two years - Bloomberg
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Paramount Skydance to close WBD deal, change ticker to SKYD
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
July 27, 2026 7:00 AM EDTNEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in the trade secret misappropriation and breach of contract litigation against... More



